Pharmacological studies have shown that CRF1 receptor antagonist, 5-HT1 receptor agonist, and adrenoreceptor antagonist can decrease depression-like behaviors, indicating that endogenous systems of CRF and monoamines including 5-HT and NE in the brain contribute to development of depression [31-34]. The gene discussed is CRH; the disease is depressive symptom measurement.